A Phillips1,2, R Strobl3,4, S Vogt5, K-H Ladwig5,6, B Thorand5, E Grill3,4. 1. Institute for Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität München, Munich, Germany. amanda.phillips@med.uni-muenchen.de. 2. German Center for Vertigo and Balance Disorders, Ludwig-Maximilians-Universität München, Munich, Germany. amanda.phillips@med.uni-muenchen.de. 3. Institute for Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität München, Munich, Germany. 4. German Center for Vertigo and Balance Disorders, Ludwig-Maximilians-Universität München, Munich, Germany. 5. Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Munich, Germany. 6. Department for Psychosomatic Medicine and Psychotherapy, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
Abstract
We estimated the prevalence of sarcopenia and its impact on disability in older people. Sarcopenia was found to contribute to higher disability scores. However, our study was not able to show any influence of sarcopenia on the rate of functional decline. This directs attention to an accurate diagnosis of sarcopenia as the onset may be influenced, but its rate may not. INTRODUCTION: The objectives of this study using data from a population-based cohort were to estimate the prevalence of sarcopenia in older people in Germany and to test the hypothesis that sarcopenia is associated with disability in older adults. METHODS: Cross-sectional (n = 927) and longitudinal analyses (n = 859) of participants aged ≥65 years at baseline from southern Germany enrolled in the Cooperative Health Research in the Region Augsburg (KORA)-Age study (2009-2012). Sarcopenia was defined based on the European Working Group on Sarcopenia in Older People (EWGSOP) algorithm which includes the presence of both low muscle mass and low muscle function (strength or performance). Disability status was measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI). The presence of disability was defined as HAQ-DI >0. Directed acyclic graphs (DAGs) were constructed to identify potential confounders. The effect of sarcopenia on disability was analyzed using linear mixed effect models with disability values as a continuous outcome. RESULTS: The overall prevalence of sarcopenia was 5.7% (men 4.0%, women 7.5%) and increased with age. The 3-year incidence of disability was 32.7%. After adjustment for potential confounders, presence of sarcopenia was significantly associated with higher disability scores (0.142 [confidence interval 0.029-0.254]). CONCLUSION: The prevalence of sarcopenia is consistent with estimates from other European studies using this algorithm. Our results suggest that sarcopenia can contribute to higher disability scores in older adults. However, our study was not able to show any influence of sarcopenia on the rate of functional decline using the EWGSOP diagnostic algorithm for sarcopenia. This directs attention to an accurate diagnosis of sarcopenia as the onset may be influenced, but its rate may not.
We estimated the prevalence of sarcopenia and its impact on disability in older people. Sarcopenia was found to contribute to higher disability scores. However, our study was not able to show any influence of sarcopenia on the rate of functional decline. This directs attention to an accurate diagnosis of sarcopenia as the onset may be influenced, but its rate may not. INTRODUCTION: The objectives of this study using data from a population-based cohort were to estimate the prevalence of sarcopenia in older people in Germany and to test the hypothesis that sarcopenia is associated with disability in older adults. METHODS: Cross-sectional (n = 927) and longitudinal analyses (n = 859) of participants aged ≥65 years at baseline from southern Germany enrolled in the Cooperative Health Research in the Region Augsburg (KORA)-Age study (2009-2012). Sarcopenia was defined based on the European Working Group on Sarcopenia in Older People (EWGSOP) algorithm which includes the presence of both low muscle mass and low muscle function (strength or performance). Disability status was measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI). The presence of disability was defined as HAQ-DI >0. Directed acyclic graphs (DAGs) were constructed to identify potential confounders. The effect of sarcopenia on disability was analyzed using linear mixed effect models with disability values as a continuous outcome. RESULTS: The overall prevalence of sarcopenia was 5.7% (men 4.0%, women 7.5%) and increased with age. The 3-year incidence of disability was 32.7%. After adjustment for potential confounders, presence of sarcopenia was significantly associated with higher disability scores (0.142 [confidence interval 0.029-0.254]). CONCLUSION: The prevalence of sarcopenia is consistent with estimates from other European studies using this algorithm. Our results suggest that sarcopenia can contribute to higher disability scores in older adults. However, our study was not able to show any influence of sarcopenia on the rate of functional decline using the EWGSOP diagnostic algorithm for sarcopenia. This directs attention to an accurate diagnosis of sarcopenia as the onset may be influenced, but its rate may not.
Authors: John E Morley; Angela Marie Abbatecola; Josep M Argiles; Vickie Baracos; Juergen Bauer; Shalender Bhasin; Tommy Cederholm; Andrew J Stewart Coats; Steven R Cummings; William J Evans; Kenneth Fearon; Luigi Ferrucci; Roger A Fielding; Jack M Guralnik; Tamara B Harris; Akio Inui; Kamyar Kalantar-Zadeh; Bridget-Anne Kirwan; Giovanni Mantovani; Maurizio Muscaritoli; Anne B Newman; Filippo Rossi-Fanelli; Giuseppe M C Rosano; Ronenn Roubenoff; Morris Schambelan; Gerald H Sokol; Thomas W Storer; Bruno Vellas; Stephan von Haehling; Shing-Shing Yeh; Stefan D Anker Journal: J Am Med Dir Assoc Date: 2011-07 Impact factor: 4.669
Authors: MaryFran R Sowers; Mary Crutchfield; Kerry Richards; Margaret K Wilkin; Anna Furniss; Mary Jannausch; Daowen Zhang; Melissa Gross Journal: J Gerontol A Biol Sci Med Sci Date: 2005-04 Impact factor: 6.053
Authors: Lena Sophie Kiefer; Jana Fabian; Roberto Lorbeer; Jürgen Machann; Corinna Storz; Mareen Sarah Kraus; Elke Wintermeyer; Christopher Schlett; Frank Roemer; Konstantin Nikolaou; Annette Peters; Fabian Bamberg Journal: Br J Radiol Date: 2018-05-03 Impact factor: 3.039
Authors: N Reid; G N Healy; J Gianoudis; M Formica; P A Gardiner; E E Eakin; C A Nowson; R M Daly Journal: Osteoporos Int Date: 2018-02-26 Impact factor: 4.507